Yugeesh R Lankadeva1, Junko Kosaka1, Roger G Evans2, Rinaldo Bellomo3, Clive N May1. 1. Pre-clinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia. 2. Cardiovascular Disease Program, Bioscience Discovery Institute and Department of Physiology, Monash University, Melbourne, VIC, Australia. 3. Department of Intensive Care and Department of Medicine, Austin Health, Heidelberg and The Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC, Australia.
Abstract
OBJECTIVES: Angiotensin II is an emerging therapy for septic acute kidney injury, but it is unknown if its vasoconstrictor action induces renal hypoxia. We therefore examined the effects of angiotensin II on intrarenal PO2 in ovine sepsis. We also assessed the validity of urinary PO2 as a surrogate measure of medullary PO2. DESIGN: Interventional study. SETTING: Research Institute. SUBJECTS: Sixteen adult Merino ewes (n = 8/group). INTERVENTIONS: Sheep were instrumented with fiber-optic probes in the renal cortex, medulla, and within a bladder catheter to measure PO2. Conscious sheep were infused with Escherichia coli for 32 hours. At 24-30 hours, angiotensin II (0.5-33.0 ng/kg/min) or saline vehicle was infused. MEASUREMENTS AND MAIN RESULTS: Septic acute kidney injury was characterized by hypotension and a 60% ± 6% decrease in creatinine clearance. During sepsis, medullary PO2 decreased from 36 ± 1 to 30 ± 3 mm Hg after 1 hour and to 20 ± 2 mm Hg after 24 hours; at these times, urinary PO2 was 42 ± 2, 34 ± 2, and 23 ± 2 mm Hg. Increases in urinary neutrophil gelatinase-associated lipocalin (12% ± 3%) and serum creatinine (60% ± 23%) were only detected at 8 and 24 hours, respectively. IV infusion of angiotensin II, at 24 hours of sepsis, restored arterial pressure and improved creatinine clearance, while not exacerbating medullary or urinary hypoxia. CONCLUSIONS: In septic acute kidney injury, renal medullary and urinary hypoxia developed several hours before increases in currently used biomarkers. Angiotensin II transiently improved renal function without worsening medullary hypoxia. In septic acute kidney injury, angiotensin II appears to be a safe, effective therapy, and urinary PO2 may be used to detect medullary hypoxia.
OBJECTIVES: Angiotensin II is an emerging therapy for septic acute kidney injury, but it is unknown if its vasoconstrictor action induces renal hypoxia. We therefore examined the effects of angiotensin II on intrarenal PO2 in ovine sepsis. We also assessed the validity of urinary PO2 as a surrogate measure of medullary PO2. DESIGN: Interventional study. SETTING: Research Institute. SUBJECTS: Sixteen adult Merino ewes (n = 8/group). INTERVENTIONS:Sheep were instrumented with fiber-optic probes in the renal cortex, medulla, and within a bladder catheter to measure PO2. Conscious sheep were infused with Escherichia coli for 32 hours. At 24-30 hours, angiotensin II (0.5-33.0 ng/kg/min) or saline vehicle was infused. MEASUREMENTS AND MAIN RESULTS:Septic acute kidney injury was characterized by hypotension and a 60% ± 6% decrease in creatinine clearance. During sepsis, medullary PO2 decreased from 36 ± 1 to 30 ± 3 mm Hg after 1 hour and to 20 ± 2 mm Hg after 24 hours; at these times, urinary PO2 was 42 ± 2, 34 ± 2, and 23 ± 2 mm Hg. Increases in urinary neutrophil gelatinase-associated lipocalin (12% ± 3%) and serum creatinine (60% ± 23%) were only detected at 8 and 24 hours, respectively. IV infusion of angiotensin II, at 24 hours of sepsis, restored arterial pressure and improved creatinine clearance, while not exacerbating medullary or urinary hypoxia. CONCLUSIONS: In septic acute kidney injury, renal medullary and urinary hypoxia developed several hours before increases in currently used biomarkers. Angiotensin II transiently improved renal function without worsening medullary hypoxia. In septic acute kidney injury, angiotensin II appears to be a safe, effective therapy, and urinary PO2 may be used to detect medullary hypoxia.
Authors: Sadudee Peerapornratana; Carlos L Manrique-Caballero; Hernando Gómez; John A Kellum Journal: Kidney Int Date: 2019-06-07 Impact factor: 10.612
Authors: Holger Scholz; Felix J Boivin; Kai M Schmidt-Ott; Sebastian Bachmann; Kai-Uwe Eckardt; Ute I Scholl; Pontus B Persson Journal: Nat Rev Nephrol Date: 2021-02-05 Impact factor: 28.314
Authors: Nikhil Mistry; C David Mazer; John G Sled; Alan H Lazarus; Lindsay S Cahill; Max Solish; Yu-Qing Zhou; Nadya Romanova; Alexander G M Hare; Allan Doctor; Joseph A Fisher; Keith R Brunt; Jeremy A Simpson; Gregory M T Hare Journal: Am J Physiol Regul Integr Comp Physiol Date: 2018-01-10 Impact factor: 3.619
Authors: Daniel E Leisman; Jamie R Privratsky; Jake R Lehman; Mabel N Abraham; Omar Y Yaipan; Mariana R Brewer; Ana Nedeljkovic-Kurepa; Christine C Capone; Tiago D Fernandes; Robert Griffiths; William J Stein; Marcia B Goldberg; Steven D Crowley; Rinaldo Bellomo; Clifford S Deutschman; Matthew D Taylor Journal: Proc Natl Acad Sci U S A Date: 2022-08-15 Impact factor: 12.779
Authors: Neil A Hukriede; Danielle E Soranno; Veronika Sander; Tayla Perreau; Michelle C Starr; Peter S T Yuen; Leah J Siskind; Michael P Hutchens; Alan J Davidson; David M Burmeister; Sarah Faubel; Mark P de Caestecker Journal: Nat Rev Nephrol Date: 2022-02-16 Impact factor: 42.439
Authors: James A Tumlin; Raghavan Murugan; Adam M Deane; Marlies Ostermann; Laurence W Busse; Kealy R Ham; Kianoush Kashani; Harold M Szerlip; John R Prowle; Azra Bihorac; Kevin W Finkel; Alexander Zarbock; Lui G Forni; Shannan J Lynch; Jeff Jensen; Stew Kroll; Lakhmir S Chawla; George F Tidmarsh; Rinaldo Bellomo Journal: Crit Care Med Date: 2018-06 Impact factor: 7.598
Authors: Daniel E Leisman; Tiago D Fernandes; Vanesa Bijol; Mabel N Abraham; Jake R Lehman; Matthew D Taylor; Christine Capone; Omar Yaipan; Rinaldo Bellomo; Clifford S Deutschman Journal: Kidney Int Date: 2020-08-31 Impact factor: 10.612
Authors: Gregory M T Hare; Melina P Cazorla-Bak; S F Michelle Ku; Kyle Chin; Nikhil Mistry; Michael C Sklar; Katerina Pavenski; Ahmad Alli; Adriaan Van Rensburg; Jan O Friedrich; Andrew J Baker; C David Mazer Journal: Can J Anaesth Date: 2020-08-07 Impact factor: 6.713